
Carla Mamolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/153750/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review. Future Oncology, 2022, , .	2.4	3
2	Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review. JMIR Cancer, 2022, 8, e39068.	2.4	2
3	Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia. Pharmacoeconomics, 2021, 39, 121-131.	3.3	3
4	An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion, 2021, 37, 801-809.	1.9	3
5	Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting. Applied Health Economics and Health Policy, 2021, 19, 929-940.	2.1	5
6	Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients. Future Oncology, 2021, 17, 2883-2892.	2.4	2
7	<p>Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 693-709.	1.9	24
8	A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC Dermatology, 2019, 19, 8.	2.1	8
9	Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion, 2019, 35, 1615-1622.	1.9	13
10	Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program. Acta Dermato-Venereologica, 2018, 98, 340-345.	1.3	20
11	Treatment patterns and outcomes among adults admitted to hospital in the U.K. due to plaque or erythrodermic psoriasis. British Journal of Dermatology, 2017, 177, e52-e54.	1.5	1
12	Effect of tofacitinib withdrawal and reâ€treatment on patientâ€reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 323-332.	2.4	21
13	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatology, 2016, 16, 15.	2.1	77
14	Tofacitinib improves pruritus and health-related quality of life up to 52Âweeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 1162-1170.e3.	1.2	57
15	Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patientâ€reported outcomes from a Phase 3 study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1753-1759.	2.4	42
16	The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. Journal of Dermatological Treatment, 2015, 26, 19-22.	2.2	31
17	Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterology, 2015, 15, 14.	2.0	76
18	Tofacitinib (<scp>CP</scp> â€690,550), an oral Janus kinase inhibitor, improves patientâ€reported outcomes in a phase 2b, randomized, doubleâ€blind, placeboâ€controlled study in patients with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 192-203.	2.4	59

#	Article	IF	CITATIONS
19	Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Quality of Life Research, 2013, 22, 2489-2499.	3.1	36